SLC5A2 and plasma cell myeloma: In our analysis, we noted significantly increased risks of mortality associated with SGLT2 inhibitors, including in AML (HR 2.00, 95% CI 1.22–3.29, p = 0.006), multiple myeloma (HR 2.27, 95% CI 1.41–3.65, p < 0.001), and CML (HR 2.68, 95% CI 1.02–7.03, p = 0.046) (Table 4).